InvestSMART

Aroa Biosurgery Limited (ASX:ARX)

ALERT: Price-sensitive ASX Announcement for ARX
Current share price for ARX : $0.540 -0.01 (-1.82%)+
Announcement
Release
30 Apr 2026 8:24AM
Price at Release
$0.550
Full Release
download
Summary
Aroa Biosurgery Limited has announced preliminary unaudited results for the fiscal year ended March 31, 2026, reporting a revenue of NZ$104 million, surpassing its guidance. The company also noted a normalised EBITDA of NZ$11-12 million, attributed to robust sales growth in its Myriad™ portfolio. The results benefited from favorable foreign exchange rates. Aroa, which focuses on healing complex wounds using proprietary technology, plans to release its audited results on May 26, 2026, and will discuss them in an investor webinar. The company’s products are significantly distributed in the U.S. market.
Key Points
  • Aroa Biosurgery Limited reported preliminary unaudited results for FY26 with total revenue of NZ$104 million.
  • The company's normalised EBITDA is expected to be between NZ$11-12 million.
  • Revenue growth was driven by strong sales in the Myriad™ portfolio, with a 52% increase in constant currency on FY25 sales.
  • Favorable foreign exchange movements positively impacted actual revenue and EBITDA results.
  • The company plans to release fully audited FY26 results on 26 May 2026 and will host an investor webinar.
  • Aroa Biosurgery specializes in soft-tissue regeneration products, using its proprietary AROA ECM™ technology.
  • The company's products are widely distributed in the United States through direct sales and partnership with TELABio, Inc.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.